Clinical Research Directory

Inclusion Criteria: * Patients with histologically and/or radiologically confirmed diagnosis of metastatic colorectal carcinoma. * Both genders. * Age ≥ 18 years old, and ≤ 75 years old. * Performance status 0-1 according to the Eastern Cooperative Oncology Group (ECOG). * Patients with adequate hematologic parameters (white blood cell count ≥3000/mm3, granulocytes ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin ≥ 8 gm/l). * Patients with adequate renal functions (serum creatinine ≤1.5 mg/dL). * Patients with adequate hepatic functions (bilirubin ≤1.5 mg/dL or albumin ≥3 g/dL). Exclusion Criteria: * Patients with active liver diseases (chronic viral hepatitis, autoimmune hepatitis, alcoholic hepatitis, Wilson's disease, hemochromatosis, or cirrhosis). * Patients with brain metastasis. * Patients with active infection. * Patients on chronic use of corticosteroids. * Patients receiving blood thinning agents(aspirin, clopidogrel, warfarin) * Patients with other malignancy (synchronous, or metachronous) * Prior exposure to neurotoxic drugs (oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel, INH) for at least 6 months prior the study treatment. * Evidence of pre-existing peripheral neuropathy resulting from another reason (diabetes, brain tumor, brain trauma, HCV, thyroid disorder). * Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases, hepatitis C. * History of known allergy to oxaliplatin or other platinum agents. * Patients with moderate and severe renal impairment (CrCl \<50 ml/min) or serum creatinine \>1.5 mg/dl. * Pregnant and breastfeeding women.